| Old Articles: <Older 6601-6610 Newer> |
|---|
 |
The Motley Fool
August 23, 2010
Jordan DiPietro |
How Safe Are Eli Lilly's Dividends? Check out how Eli Lilly stacks up   |
The Motley Fool
August 23, 2010
Brian Orelli |
No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
August 20, 2010
Brian Orelli |
Depression Is Painful. Advisory Panels More So. Eli Lilly's Cymbalta has a rough time in from of the panel of experts. |
The Motley Fool
August 19, 2010
Jeremy Phillips |
The One Thing to Know About Continucare Are Continucare CEO Richard Pfenniger's interests aligned with shareholders? Here's how the Continucare CEO's ownership compares to that of his peers in the health care services industry. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
The Motley Fool
August 19, 2010
Brian Orelli |
High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
August 18, 2010
Brian Orelli |
More Pain Ahead for Eli Lilly? An advisory panel meeting tomorrow could further the company's slide. |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
| <Older 6601-6610 Newer> Return to current articles. |
